Skip to main content

Table 2 Definition of poor risk localised disease and indications for busulfan and melphalan (BuMel) high-dose therapy

From: International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours – EURO EWING 2012 Protocol

CaseLocalised diseaseResected at diagnosisVolume ≥200 mLPre-operative RTHistological response
≥10% viable tumour
Unresectable tumour treated with RT aloneVolume <200 mL but poor radiological response i.e., <50% regression with chemotherapyRT contraindications to BuMelaOther medical contraindications to BuMelaBuMel recommended
1Nn/rn/rn/rn/rn/rn/rn/rn/rN
2YYNn/rn/rn/rn/rn/rn/rN
3YYYn/rn/rn/rn/rNNY
4YNNn/rYn/rn/rNNY
5YNNYYn/rn/rNNY
6YNYNYn/rn/rNNY
7YNYYYn/rn/rNNY
8YNYYNn/rn/rNNY
9YNYYn/abn/rn/rNNY
10YNYNn/aYn/rNNY
11YNNNn/aYYNNY
  1. n/a not available, n/r not relevant, RT radiotherapy
  2. aIf response is yes, then high-dose therapy is contraindicated
  3. bFor example, if extracorporeal irradiation of primary tumour is used prior to re-implantation